With Some Help Small Canadian Biotech Could Challenge Roche's Hold in Stroke Treatment

Retrieved on: 2022-07-29 16:11:38

Tags for this article:

Drugs

Health care

Medical specialties

Alteplase

Boehringer Ingelheim

Tissue plasminogen activator

Stroke

Genentech

Plasminogen activator

Click the tags to see associated articles and topics

With Some Help Small Canadian Biotech Could Challenge Roche's Hold in Stroke Treatment. View article details on hiswai: https://www.biospace.com/article/small-biotech-nervgen-challenges-roche-stroke-treatment/

Excerpt

NervGen showed that its proprietary drug NVG-291-R could repair the nervous system after a stroke—even when it was given up to seven days after ...

Article found on: www.biospace.com

View Original Article